Combination avelumab and axitinib treatment of advanced type B3 thymoma and thymic carcinoma is promising as second-line treatment after standard therapy.
1. Patients who had never previously received anti-angiogenesis treatments had longer progression-free survival 2. Adverse events of combination avelumab and ...